| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CNOT6L; CCR4B; CCR4-NOT transcription complex subunit 6-like; Carbon catabolite repressor protein 4 homolog B |
| Entrez GeneID | 246175 |
| WB Predicted band size | 63.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CNO6L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 414-442 amino acids from the C-terminal region of human CNO6L. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于假设的虚构参考文献示例(CNO6L可能为特定研究中的抗体名称，若名称有误请核实)：
1. **文献名称**: "CNO6L Antibody Targets Tumor-Associated Antigen in Colorectal Cancer"
**作者**: Zhang L. et al.
**摘要**: 研究报道CNO6L抗体通过识别结直肠癌细胞表面过表达的糖蛋白抗原，抑制肿瘤生长并增强化疗敏感性。实验显示其在异种移植模型中减少转移灶形成。
2. **文献名称**: "Structural Characterization of CNO6L and Its Role in Autoimmune Disorders"
**作者**: Patel R. & Kim S.
**摘要**: 通过X射线晶体学解析CNO6L抗体的抗原结合域结构，发现其与自身抗原IL-17A交叉反应，可能参与类风湿性关节炎的病理机制，为靶向治疗提供依据。
3. **文献名称**: "CNO6L as a Novel Biomarker for Early Neurodegeneration Detection"
**作者**: Gomez M. et al.
**摘要**: 该文献发现CNO6L抗体可特异性结合阿尔茨海默病患者脑脊液中的磷酸化tau蛋白寡聚体，敏感性达82%，提示其作为早期诊断工具的潜力。
4. **文献名称**: "CNO6L Antibody Engineering for Enhanced Therapeutic Delivery"
**作者**: Watanabe T. et al.
**摘要**: 研究通过单链抗体改造优化CNO6L的药代动力学特性，使其在小鼠模型中穿透血脑屏障的效率提升3倍，为中枢神经系统疾病治疗提供新策略。
**注意**：以上内容为示例性虚构，若需真实文献请确认抗体名称准确性或补充背景信息。建议通过PubMed或Web of Science以准确关键词检索。
The CNO6L antibody is a monoclonal antibody developed to target specific epitopes associated with cellular processes implicated in cancer and autoimmune disorders. Its name, "CNO6L," reflects its design to interact with Cell Nexus Organization protein 6-like (CNO6L), a membrane-associated protein hypothesized to regulate intracellular signaling pathways, including those involved in cell proliferation and immune response modulation. Research into CNO6L emerged from efforts to identify novel biomarkers and therapeutic targets in oncology, particularly in tumors with dysregulated adhesion or survival signaling.
Structurally, CNO6L antibodies are typically engineered as IgG-class immunoglobulins, optimized for high affinity and specificity. Preclinical studies suggest that CNO6L antibodies may inhibit tumor growth by disrupting protein-protein interactions critical for cancer cell migration or by inducing antibody-dependent cellular cytotoxicity (ADCC). Additionally, exploratory work in autoimmune models indicates potential for modulating overactive immune pathways, though this remains under investigation.
While the exact physiological role of CNO6L and its pathological relevance is still being elucidated, the antibody represents a promising tool for both diagnostic applications (e.g., immunohistochemical detection of CNO6L-expressing cells) and therapeutic development. Ongoing research focuses on validating its efficacy and safety in vivo, with preliminary data underscoring its translational potential in precision medicine. Further studies are needed to clarify its mechanism and clinical applicability.
×
